EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival

Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B

A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.

alt

Read more:

EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates

Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.

alt

Read more:

EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List

Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.

alt

Read more: